首页 > 最新文献

American Journal of Geriatric Psychiatry最新文献

英文 中文
Commentary: The Effect of Stress on All-Cause Dementia: A Longitudinal Analysis from the Australian Longitudinal Study on Women’s Health 评论:压力对全因痴呆的影响:来自澳大利亚妇女健康纵向研究的纵向分析。
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-12-06 DOI: 10.1016/j.jagp.2025.12.001
Robert H. Pietrzak Ph.D., M.P.H. , Peter J. Na M.D., M.P.H. , Yen Ying Lim Ph.D.
{"title":"Commentary: The Effect of Stress on All-Cause Dementia: A Longitudinal Analysis from the Australian Longitudinal Study on Women’s Health","authors":"Robert H. Pietrzak Ph.D., M.P.H. , Peter J. Na M.D., M.P.H. , Yen Ying Lim Ph.D.","doi":"10.1016/j.jagp.2025.12.001","DOIUrl":"10.1016/j.jagp.2025.12.001","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 3","pages":"Pages 281-283"},"PeriodicalIF":3.8,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145852203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Music Listening as a Low-Risk Adjunct to Delirium Prevention: Translating Evidence to the Ward 听音乐作为预防谵妄的低风险辅助手段:将证据翻译到病房。
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-12-06 DOI: 10.1016/j.jagp.2025.11.020
Chenlei Sun Ph.D. , Ke Meng Ph.D. , Xiaomeng Zhu Ph.D.
{"title":"Music Listening as a Low-Risk Adjunct to Delirium Prevention: Translating Evidence to the Ward","authors":"Chenlei Sun Ph.D. , Ke Meng Ph.D. , Xiaomeng Zhu Ph.D.","doi":"10.1016/j.jagp.2025.11.020","DOIUrl":"10.1016/j.jagp.2025.11.020","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 3","pages":"Pages 397-398"},"PeriodicalIF":3.8,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which Type of Group Activity has the Greatest Impact on the Well-Being of Persons With Dementia? An Exploration of a Study of Enhanced Group Activity Kits 哪种类型的团体活动对痴呆症患者的健康影响最大?增强小组活动工具包的研究探索。
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-12-05 DOI: 10.1016/j.jagp.2025.12.003
Jiska Cohen-Mansfield Ph.D.

Objectives

Group activities for persons living with dementia (PLwD) can enhance their well-being, mental health, and affect; however, little is known about how activity type influences outcomes. This study examines the relative impact of activity type on well-being within the context of Enhanced Group Activity Kits (EGAKs).

Design

This is a secondary analysis of a stepped wedge clustered trial introducing EGAKs sequentially across settings.

Settings

Six nursing care units and four senior day center units in Israel.

Participants

One hundred fifteen PLwD who resided in or attended these settings.

Intervention

Forty seven EGAK-facilitated group activities in eight categories, including singing, creative arts, reading and discussion, and travel around the world, led by staff members.

Measurements

Research observers and activity leaders independently rated participants’ responses via the group observational measurement of engagement, from which the well-being index was derived. Mixed models analyses compared well-being across categories and within categories, controlling for participants’ cognitive function.

Results

All 47 EGAKs yielded maximum well-being scores for at least one participant. Significant differences emerged across categories: physical exercise, creative arts, singing, and Jewish texts reading/discussion achieved the highest well-being, whereas travel around the world and art history elicited the lowest. Within-category analyses showed significant variations within six of the eight categories. Correspondingly, the ranking of mean well-being for some kits diverged from others within their category.

Conclusions

While certain categories consistently promoted well-being, effectiveness depended on activity characteristics, such as personal relevance and cognitive accessibility. These findings suggest that tailoring activity content and delivery may be more important than activity type in enhancing well-being for PLwD.
目的:为痴呆症患者(PLwD)举办的团体活动可以改善他们的福祉、心理健康和影响;然而,人们对运动类型如何影响结果知之甚少。本研究考察了活动类型在增强小组活动工具包(EGAKs)背景下对幸福感的相对影响。设计:这是一个阶梯式楔形聚类试验的二次分析,在不同的设置中依次引入egak。环境:以色列的六个护理单位和四个老年日间中心单位。参与者:115名居住或参加这些设置的PLwD。干预:在工作人员的带领下,开展了47项由egak推动的小组活动,包括唱歌、创意艺术、阅读和讨论、环游世界等8个类别。测量方法:研究观察员和活动领导者通过参与度的群体观察测量来独立评估参与者的反应,幸福指数由此衍生。混合模型分析比较了不同类别和类别内的幸福感,控制了参与者的认知功能。结果:所有47个egak至少对一个参与者产生了最大的幸福感得分。不同类别之间存在显著差异:体育锻炼、创意艺术、唱歌和犹太文本阅读/讨论获得的幸福感最高,而环游世界和艺术史的幸福感最低。类别内分析显示,8个类别中有6个类别存在显著差异。相应地,一些工具包的平均福利排名与其类别中的其他工具包不同。结论:虽然某些类别持续促进幸福感,但有效性取决于活动特征,如个人相关性和认知可及性。这些发现表明,在提高PLwD的幸福感方面,量身定制活动内容和方式可能比活动类型更重要。
{"title":"Which Type of Group Activity has the Greatest Impact on the Well-Being of Persons With Dementia? An Exploration of a Study of Enhanced Group Activity Kits","authors":"Jiska Cohen-Mansfield Ph.D.","doi":"10.1016/j.jagp.2025.12.003","DOIUrl":"10.1016/j.jagp.2025.12.003","url":null,"abstract":"<div><h3>Objectives</h3><div>Group activities for persons living with dementia (PLwD) can enhance their well-being, mental health, and affect; however, little is known about how activity type influences outcomes. This study examines the relative impact of activity type on well-being within the context of Enhanced Group Activity Kits (EGAKs).</div></div><div><h3>Design</h3><div>This is a secondary analysis of a stepped wedge clustered trial introducing EGAKs sequentially across settings.</div></div><div><h3>Settings</h3><div>Six nursing care units and four senior day center units in Israel.</div></div><div><h3>Participants</h3><div>One hundred fifteen PLwD who resided in or attended these settings.</div></div><div><h3>Intervention</h3><div>Forty seven EGAK-facilitated group activities in eight categories, including singing, creative arts, reading and discussion, and travel around the world, led by staff members.</div></div><div><h3>Measurements</h3><div>Research observers and activity leaders independently rated participants’ responses via the group observational measurement of engagement, from which the well-being index was derived. Mixed models analyses compared well-being across categories and within categories, controlling for participants’ cognitive function.</div></div><div><h3>Results</h3><div>All 47 EGAKs yielded maximum well-being scores for at least one participant. Significant differences emerged across categories: physical exercise, creative arts, singing, and Jewish texts reading/discussion achieved the highest well-being, whereas travel around the world and art history elicited the lowest. Within-category analyses showed significant variations within six of the eight categories. Correspondingly, the ranking of mean well-being for some kits diverged from others within their category.</div></div><div><h3>Conclusions</h3><div>While certain categories consistently promoted well-being, effectiveness depended on activity characteristics, such as personal relevance and cognitive accessibility. These findings suggest that tailoring activity content and delivery may be more important than activity type in enhancing well-being for PLwD.</div></div>","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 3","pages":"Pages 337-347"},"PeriodicalIF":3.8,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lost and Found: A 78th Birthday Meditation 《失物招领:78岁生日冥想
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-11-26 DOI: 10.1016/j.jagp.2025.08.009
David L. Coulter M.D.
{"title":"Lost and Found: A 78th Birthday Meditation","authors":"David L. Coulter M.D.","doi":"10.1016/j.jagp.2025.08.009","DOIUrl":"10.1016/j.jagp.2025.08.009","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 1","pages":"Pages 144-145"},"PeriodicalIF":3.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Information for Subscribers 订户资讯
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-11-26 DOI: 10.1016/S1064-7481(25)00514-7
{"title":"Information for Subscribers","authors":"","doi":"10.1016/S1064-7481(25)00514-7","DOIUrl":"10.1016/S1064-7481(25)00514-7","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 1","pages":"Page A1"},"PeriodicalIF":3.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Substance use disorders in later life: a review and synthesis of the literature of an emerging public health concern” Am J Geriatr Psychiatry, 2020, 28(2): 226–236 “老年生活中的物质使用障碍:对新出现的公共卫生问题的文献回顾和综合”,《老年精神病学杂志》,2020,28(2):226-236。
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-11-23 DOI: 10.1016/j.jagp.2025.11.012
Stephanie Yarnell M.D., Ph.D , Luming Li M.D., M.H.S. , Brian MacGrory MB BCh BAO, M.H.S., MRCP , Louis Trevisan M.D. , Paul Kirwin M.D.
{"title":"Corrigendum to “Substance use disorders in later life: a review and synthesis of the literature of an emerging public health concern” Am J Geriatr Psychiatry, 2020, 28(2): 226–236","authors":"Stephanie Yarnell M.D., Ph.D ,&nbsp;Luming Li M.D., M.H.S. ,&nbsp;Brian MacGrory MB BCh BAO, M.H.S., MRCP ,&nbsp;Louis Trevisan M.D. ,&nbsp;Paul Kirwin M.D.","doi":"10.1016/j.jagp.2025.11.012","DOIUrl":"10.1016/j.jagp.2025.11.012","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 2","pages":"Page 267"},"PeriodicalIF":3.8,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reflections on a Study of Low-Dose Agomelatine as Add-on for Agitation in Alzheimer’s Disease 小剂量阿戈美拉汀加药治疗阿尔茨海默病躁动的研究思考
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-11-22 DOI: 10.1016/j.jagp.2025.11.011
Sumedha Saha M.B.B.S., Skarma Spalzang M.D., Susanta Kumar Padhy M.D., Arpit Parmar M.D., D.M.
{"title":"Reflections on a Study of Low-Dose Agomelatine as Add-on for Agitation in Alzheimer’s Disease","authors":"Sumedha Saha M.B.B.S.,&nbsp;Skarma Spalzang M.D.,&nbsp;Susanta Kumar Padhy M.D.,&nbsp;Arpit Parmar M.D., D.M.","doi":"10.1016/j.jagp.2025.11.011","DOIUrl":"10.1016/j.jagp.2025.11.011","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 3","pages":"Pages 405-406"},"PeriodicalIF":3.8,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145759377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain, Body, and Equity: A Pathway to Healthy Aging 大脑,身体和公平:健康老龄化的途径。
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-11-21 DOI: 10.1016/j.jagp.2025.11.008
Hanadi Ajam Oughli M.D., Helen Lavretsky M.D., M.S.
{"title":"Brain, Body, and Equity: A Pathway to Healthy Aging","authors":"Hanadi Ajam Oughli M.D.,&nbsp;Helen Lavretsky M.D., M.S.","doi":"10.1016/j.jagp.2025.11.008","DOIUrl":"10.1016/j.jagp.2025.11.008","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 2","pages":"Pages 164-166"},"PeriodicalIF":3.8,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dronabinol for Agitation in Alzheimer’s Disease 屈大麻酚治疗阿尔茨海默病的躁动。
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-11-12 DOI: 10.1016/j.jagp.2025.11.006
Rajesh R. Tampi M.D., M.S., D.F.A.P.A., D.F.A.A.G.P.
{"title":"Dronabinol for Agitation in Alzheimer’s Disease","authors":"Rajesh R. Tampi M.D., M.S., D.F.A.P.A., D.F.A.A.G.P.","doi":"10.1016/j.jagp.2025.11.006","DOIUrl":"10.1016/j.jagp.2025.11.006","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 2","pages":"Pages 180-182"},"PeriodicalIF":3.8,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer’s Disease 屈大麻酚治疗阿尔茨海默病躁动的安全性和有效性的随机对照试验。
IF 3.8 2区 医学 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-11-10 DOI: 10.1016/j.jagp.2025.10.011
Paul B. Rosenberg M.D. , Halima Amjad M.D., M.P.H., Ph.D. , Haroon Burhanullah M.D. , Milap Nowrangi M.D. , Ryan Vandrey Ph.D. , Mersania Jn Pierre B.A. , John D. Outen M.S. , Meghan Schultz R.N., M.S.N , Christopher Marano M.D. , Marc Agronin M.D. , James M. Wilkins M.D., D.Phil. , David Harper Ph.D. , Todd Laffaye B.A. , Eilis Reardon B.A. , Kathryn Turner B.A. , Rosain Ozonsi B.S. , Mia Drury B.A. , Andre Nguyen B.S. , Tuna Hasoğlu M.D. , Julia Cromwell M.D. , Brent P. Forester M.D., M.Sc.

Importance

Agitation in Alzheimer’s disease (AD) is a great source of distress for patients and caregivers and a major public health burden. Current treatments are only modestly effective and many have safety issues including mortality risk. Novel therapeutic options are needed. There is preliminary evidence for the safety and efficacy of dronabinol (tetrahydrocannabinol, THC) for agitation in AD.

Objective

Assess the safety and efficacy of dronabinol (THC) to decrease agitation in AD.

Design

THC-AD was a 3-week randomized parallel double-blind placebo-controlled clinical trial, conducted between 2017 and 2024.

Setting

5 inpatient and outpatient academic clinical research centers in the Eastern U.S.

Participants

Volunteer sample of 75 participants meeting inclusion criteria for agitation of AD (International Psychogeriatric Association Provision Criteria) with Neuropsychiatric Inventory Clinician Version Agitation or Aggression (NPI-C A/A) domains total score of 4 or greater. Major exclusion criteria included seizure disorder, delirium, and non-AD dementia.

Interventions

3 weeks dronabinol vs. placebo titrated up to target dose of 10 mg daily in divided twice-daily.

Main Outcomes and Measures

Prespecified co-primary agitation outcomes were the Pittsburgh Agitation Scale (PAS) and NPI-C A/A total score.

Results

The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline. Study participants were moderately agitated at baseline, were diverse in ethnic background (9% Black, 11% Hispanic/Latina/Latino), and had severe cognitive impairment evidenced by MMSE or SIB-8. 84% completed the 3-week trial. Dronabinol decreased agitation on both primary outcomes greater than placebo to a clinically relevant extent. The fitted between-arm difference in PAS decline/week was −0.74 (SE 0.3, p = 0.015, effect size = 0.53) and for NPI-C A/A the decline was not significant at −1.26 (SE 0.67, p = 0.094, effect size = 0.36). No secondary outcomes differed between treatment arms including sleep, activities of daily living, Cohen-Mansfield Agitation Inventory (CMAI), cognition, intoxication, or use of ‘as-needed’ lorazepam or trazodone. Dronabinol treatment was not associated with greater intoxication nor with other adverse events (AEs) except for somnolence.

Conclusions and Relevance

Adjunctive dronabinol treatment was safe and effective for treating agitation in AD.

Clinical Trials Registration

NCT02792257
重要性:阿尔茨海默病(AD)的躁动是患者和护理人员痛苦的一个重要来源,也是一个主要的公共卫生负担。目前的治疗方法只有适度的效果,而且许多治疗方法存在包括死亡风险在内的安全问题。我们需要新的治疗方案。有初步证据表明,四氢大麻酚(四氢大麻酚,THC)对AD躁动的安全性和有效性。目的:评价屈大麻酚(THC)减少AD患者躁动的安全性和有效性。设计:THC-AD是一项为期3周的随机平行双盲安慰剂对照临床试验,于2017年至2024年进行。背景:美国东部5个住院和门诊学术临床研究中心参与者:75名志愿者样本符合AD躁动的纳入标准(国际老年精神病学协会提供标准),神经精神量表临床医生版本躁动或攻击(NPI-C A/A)域总分为4分或以上。主要排除标准包括癫痫发作障碍、谵妄和非ad痴呆。干预措施:3周,曲大麻酚与安慰剂滴定至目标剂量10mg,每日两次。主要结局和测量:预先指定的共同主要躁动结局是匹兹堡躁动量表(PAS)和NPI-C A/A总分。结果:大多数参与者是女性,并且在基线时同时服用精神药物(抗抑郁药和抗精神病药)。研究参与者在基线时中度激动,种族背景不同(9%为黑人,11%为西班牙裔/拉丁裔/拉丁裔),并且有严重的认知障碍,由MMSE或sibb -8证明。84%完成了为期3周的试验。在临床相关程度上,屈大麻酚对两种主要结局的躁动程度均优于安慰剂。PAS下降/周的拟合臂间差异为-0.74 (SE 0.3, p = 0.015,效应量= 0.53),NPI-C A/A的下降为-1.26 (SE 0.67, p = 0.094,效应量= 0.36)。治疗组间的次要结果无差异,包括睡眠、日常生活活动、Cohen-Mansfield躁动量表(CMAI)、认知、中毒或“按需”使用劳拉西泮或曲唑酮。除嗜睡外,地大麻酚治疗与更严重的中毒或其他不良事件(ae)无关。结论及意义:辅助屈大麻酚治疗阿尔茨海默病躁动安全有效。临床试验注册:NCT02792257。
{"title":"A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer’s Disease","authors":"Paul B. Rosenberg M.D. ,&nbsp;Halima Amjad M.D., M.P.H., Ph.D. ,&nbsp;Haroon Burhanullah M.D. ,&nbsp;Milap Nowrangi M.D. ,&nbsp;Ryan Vandrey Ph.D. ,&nbsp;Mersania Jn Pierre B.A. ,&nbsp;John D. Outen M.S. ,&nbsp;Meghan Schultz R.N., M.S.N ,&nbsp;Christopher Marano M.D. ,&nbsp;Marc Agronin M.D. ,&nbsp;James M. Wilkins M.D., D.Phil. ,&nbsp;David Harper Ph.D. ,&nbsp;Todd Laffaye B.A. ,&nbsp;Eilis Reardon B.A. ,&nbsp;Kathryn Turner B.A. ,&nbsp;Rosain Ozonsi B.S. ,&nbsp;Mia Drury B.A. ,&nbsp;Andre Nguyen B.S. ,&nbsp;Tuna Hasoğlu M.D. ,&nbsp;Julia Cromwell M.D. ,&nbsp;Brent P. Forester M.D., M.Sc.","doi":"10.1016/j.jagp.2025.10.011","DOIUrl":"10.1016/j.jagp.2025.10.011","url":null,"abstract":"<div><h3>Importance</h3><div>Agitation in Alzheimer’s disease (AD) is a great source of distress for patients and caregivers and a major public health burden. Current treatments are only modestly effective and many have safety issues including mortality risk. Novel therapeutic options are needed. There is preliminary evidence for the safety and efficacy of dronabinol (tetrahydrocannabinol, THC) for agitation in AD.</div></div><div><h3>Objective</h3><div>Assess the safety and efficacy of dronabinol (THC) to decrease agitation in AD.</div></div><div><h3>Design</h3><div>THC-AD was a 3-week randomized parallel double-blind placebo-controlled clinical trial, conducted between 2017 and 2024.</div></div><div><h3>Setting</h3><div>5 inpatient and outpatient academic clinical research centers in the Eastern U.S.</div></div><div><h3>Participants</h3><div>Volunteer sample of 75 participants meeting inclusion criteria for agitation of AD (International Psychogeriatric Association Provision Criteria) with Neuropsychiatric Inventory Clinician Version Agitation or Aggression (NPI-C A/A) domains total score of 4 or greater. Major exclusion criteria included seizure disorder, delirium, and non-AD dementia.</div></div><div><h3>Interventions</h3><div>3 weeks dronabinol vs. placebo titrated up to target dose of 10 mg daily in divided twice-daily.</div></div><div><h3>Main Outcomes and Measures</h3><div>Prespecified co-primary agitation outcomes were the Pittsburgh Agitation Scale (PAS) and NPI-C A/A total score.</div></div><div><h3>Results</h3><div>The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline. Study participants were moderately agitated at baseline, were diverse in ethnic background (9% Black, 11% Hispanic/Latina/Latino), and had severe cognitive impairment evidenced by MMSE or SIB-8. 84% completed the 3-week trial. Dronabinol decreased agitation on both primary outcomes greater than placebo to a clinically relevant extent. The fitted between-arm difference in PAS decline/week was −0.74 (SE 0.3, p = 0.015, effect size = 0.53) and for NPI-C A/A the decline was not significant at −1.26 (SE 0.67, p = 0.094, effect size = 0.36). No secondary outcomes differed between treatment arms including sleep, activities of daily living, Cohen-Mansfield Agitation Inventory (CMAI), cognition, intoxication, or use of ‘as-needed’ lorazepam or trazodone. Dronabinol treatment was not associated with greater intoxication nor with other adverse events (AEs) except for somnolence.</div></div><div><h3>Conclusions and Relevance</h3><div>Adjunctive dronabinol treatment was safe and effective for treating agitation in AD.</div></div><div><h3>Clinical Trials Registration</h3><div>NCT02792257</div></div>","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 2","pages":"Pages 167-179"},"PeriodicalIF":3.8,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American Journal of Geriatric Psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1